Table 1.
Cohort demographic and clinical characteristics.
| Patients, no. | 5 |
| Median age, years (range) | 60 (42–69) |
| BMI | 30 (22.6–36.2) |
| Sex, no. (%) | |
| Female | 3 (60) |
| Male | 2 (40) |
| Race, ethnicity | |
| White, non-Hispanic, no. (%) | 5 (100) |
| Median baseline CA 19-9, U/mL (range) | 20.5 (6.3–830.3) |
| Median baseline CHC count, per 50,000 PBMCs (range) | 13.5 (7.6–15.5) |
| Systemic therapy prior to trial enrollment | |
| Yes, no. (%) | 1 (20) |
| Regimen, cycles | Gem/Cis, 1 |
| Median dominant lesion size, cm (range) | 9.8 (8.4–14.5) |
| Median number of intrahepatic lesions, no. (range) | 9 (1–15) |
| Large vessel involvement, no. (%) | 5 (100) |
| Median follow-up from trial enrollment, months (range) | 22.7 (6.0–27.5) |
| Total number of blood samples collected, no. | 42 |
| Median number of blood samples collected per patient, no. (range) | 9 (7–10) |
| Median number of blood samples collected per patient while on trial protocol treatment, no. (range) | 7 (6–7) |
| Median number of blood samples collected per patient after completion of trial protocol treatment, no. (range) | 2 (0–3) |
Abbreviations: BMI, body mass index; CA 19-9, carbohydrate antigen 19-9; CHC, circulating hybrid cell; no., number; Gem/Cis, gemcitabine and cisplatin; PBMC, peripheral blood mononuclear cells.